BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210803
DTEND;VALUE=DATE:20210806
DTSTAMP:20260515T201513
CREATED:20210329T142632Z
LAST-MODIFIED:20210329T142632Z
UID:29572-1627948800-1628207999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy Immunogenicity Summit
DESCRIPTION:The 2nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate\, measure and predict immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges\, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you’re up to speed on the latest approaches to predict\, measure and overcome every immunogenicity challenge you encounter. \nFocused specifically on examining gene therapy immunogenicity\, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory approaches could enable re-dosing and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing approaches to address immunogenicity. \nJoin your peers online and discover: \n\nHow Chameleon Bioscience are developing an immune evasive AAV for repeat dosing\nThe impact of innate and anti-transgene immunogenicity on AAV vector-mediated gene transfer with Genethon\nStrategies to monitor anti-AAV cell-based transduction inhibition assay supporting clinical trials with Sangamo Therapeutics\nPerformances of biosafety analytical assays commonly used in gene therapy development\nImmunogenicity risk assessment for AAV-based gene therapies with Roche\nHow to define the seroprevalence and titer of pre-existing antibodies with age and geographical location with Novartis\nAAV capsid neutralizing antibodies and associated complement mediated immunotoxicties with IU Edu\nRegulatory considerations for immune responses to gene therapies with the US FDA\nRole of innate immunity in CD8+ T cell responses in AAV gene transfer with The NIH\nMitigation of AAV vector immunogenicity with tolerogenic nanoparticles with Selecta Bioscience\n\nView the full event guide now to find out more!
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-immunogenicity-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210803
DTEND;VALUE=DATE:20210806
DTSTAMP:20260515T201513
CREATED:20210416T073855Z
LAST-MODIFIED:20210416T073855Z
UID:29797-1627948800-1628207999@www.pharmajournalist.com
SUMMARY:4th Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:Translating Scientific Findings of the Skin Microbiome into Commercially Viable Therapeutics & Cosmetic Products That Improve Skin Health \nWith improvements in the tools and technologies that enable deeper analysis of the skin microbiome\, the community’s understanding of the skin microbiome is becoming clearer. This has led to the development of a number of breakthrough dermatological\, skincare and cosmetic solutions that tap into this ecosystem on our skin for improved health. \nHowever\, there still exists several unique areas of basic and clinical science within the skin microbiome field that need addressing before the true potential of this field is realized. \nCelebrating our fourth year\, the Microbiome Movement – Skin Health & Dermatology Summit continues to unite researchers from academia and industry to address the unique areas of scientific R&D\, as well as the consumer interfacing aspect of this industry. Bringing together 25+ expert speakers and 100+ key decision makers across 3 days\, we will hasten the development of microbiome-targeting therapeutics and cosmetics through a series of presentations\, panel discussions and networking opportunities. \nJoin us to fast-track the development of microbiome-targeting therapeutics and cosmetics that focus on characterization\, clinical testing and product commercialization. \nTightly focused on translating academic discussions into cosmetic and therapeutic development\, this unrivalled program addresses the latest scientific findings and key translational challenges to aid the development of your scientifically validated skin microbiome products so you can bring them to the hands of patients and consumers faster.
URL:https://www.pharmajournalist.com/event/4th-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210817
DTEND;VALUE=DATE:20210820
DTSTAMP:20260515T201513
CREATED:20210409T153003Z
LAST-MODIFIED:20210413T084608Z
UID:29760-1629158400-1629417599@www.pharmajournalist.com
SUMMARY:Prostate Cancer Drug Development Digital Summit
DESCRIPTION:The inaugural virtual Prostate Cancer Drug Development Summit lands at a crucial time as the first and only dedicated conference for large pharma\, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery\, translation\, and clinical development of safe and effective treatments for prostate cancer. \n \nHere’s a sneak peek of crucial topics to be addressed: \n\nAmgen examining Bi-specific T-cell engager immune therapies for the treatment of prostate cancer ​​​​​​\nNovartis and Advanced Accelerator Applications revealing PSMA\, re-envision survival\n​​​​​​Noxopharm evaluating whether Veyonda is the answer to safe and effective prostate cancer treatment\nThe National Cancer Institute and the National Institutes of Health teaching optimization potential role for immunotherapy in biochemically recurrent prostate cancer\nThe University of Texas\, MD Anderson Cancer Center demonstrating strategies for overcoming the immunosuppressive prostate tumor microenvironment and whether there is still a role for chemotherapy and chemotherapy combinations\n\nTo find out more and view the 2021 speaker line-up\, download the full event guide. \nJoin 60+ thought-leaders converging at the first industry-led meeting to gain the latest scientific insights with renowned Urologists/Oncologists and those striving to advance safe and effective therapeutic breakthroughs to patients in need. \nTo know more about Prostate Cancer Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/prostate-cancer-drug-development-digital-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210817
DTEND;VALUE=DATE:20210820
DTSTAMP:20260515T201513
CREATED:20210514T082011Z
LAST-MODIFIED:20210514T084343Z
UID:30139-1629158400-1629417599@www.pharmajournalist.com
SUMMARY:Integrin-Targeted Drug Discovery Summit
DESCRIPTION:The excitement surrounding integrins has been growing over the past few years\, culminating in recent clinical success\, innovative biology and medicinal chemistry advancements blazing the way to tackle previously undruggable disease modalities through novel integrin targets \nThe Integrin-Targeted Drug Discovery Summit is not just the first\, but the only industry-driven event sharing pioneering advances\, expert insights and exclusive updates on the field of integrin drug discovery and development – from solid tumors to autoimmune diseases\, from ophthalmology to fibrosis\, revealing the therapeutic windows of integrins! \nWith the vast potential of integrins as targets\, this inaugural 3-day summit will unite industry trailblazers including Pliant Therapeutics\, Morphic Therapeutics and 7 Hills Pharma with academic leaders\, such as pioneer Dean Sheppard\, to delve into the biology and chemistry of different integrins classes\, MoA and explore the best approach to regulate integrins\, driving translational and clinical success. \nJoin a global community of 80+ experts on August 17-19 to tackle issues of safety\, selectivity and specificity in drug development\, further your understanding of the structure and function of integrins to inform your R&D decisions and leverage the lessons learned over the past 20 years to enhance your bed to bedside progression. \nFind out more >> https://ter.li/g4kols
URL:https://www.pharmajournalist.com/event/integrin-targeted-drug-discovery-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210824
DTEND;VALUE=DATE:20210827
DTSTAMP:20260515T201513
CREATED:20210507T084054Z
LAST-MODIFIED:20210507T084054Z
UID:30057-1629763200-1630022399@www.pharmajournalist.com
SUMMARY:2nd Annual Biomarkers for Alzheimer’s Disease Summit
DESCRIPTION:The 2nd Annual Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement. \nBack for its 2nd year\, there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape. This industry-defining meeting delves into blood-based biomarkers\, neuroinflammatory markers and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge\, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s Disease. \nThe Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science\, convey lessons learned and network to build long lasting partnerships. \nTo know more about 2nd Annual Biomarkers for Alzheimer’s Disease Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-biomarkers-for-alzheimers-disease-summit/
LOCATION:Online Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210824
DTEND;VALUE=DATE:20210826
DTSTAMP:20260515T201513
CREATED:20210514T131808Z
LAST-MODIFIED:20210514T151641Z
UID:30182-1629763200-1629935999@www.pharmajournalist.com
SUMMARY:Neuropathic Pain Therapeutics Summit
DESCRIPTION:New this year\, the Neuropathic Pain Therapeutics digital summit is the only meeting for large pharma\, biotech and pioneering academics addressing the industry’s key challenges of understanding the underlying pathophysiology of neuropathic pain\, identifying novel therapeutic targets for neuropathic pain and more! \nWith an ageing global population and unabating opioid crisis\, the clinical need for novel neuropathic pain therapeutics has reached a critical level. This meeting will be the center point for exploring novel drug modalities for neuropathic pain including: NaV1.7 channel inhibitors\, antisense oligonucleotides\, matrix metalloproteinase inhibitors\, gene therapy\, anti-TRPV1 antibody\, cannabinoid-derived pharmaceutical\, neuroimmune-targeted\, medical device approaches and more. \nFrom harnessing preclinical models for pain drug discovery to identifying pain biomarkers and novel non-addictive neuropathic pain drug modalities in development\, this conference will delve into challenges that have obstructed the clinical success of neuropathic pain therapeutics. \nLearn from 20+ thought leaders in our expert speaker faculty\, access 18+ hours of content exploring the latest advances in the neuropathic pain therapy field and form meaningful connections during the multiple and varied hybrid networking sessions built into the event. \nJoin this industry-dedicated virtual forum as we unite drug developers and academics to tackle the most critical drug development challenges in accelerating novel neuropathic pain therapeutics into the clinic and to patients in need. \nTo know more about Neuropathic Pain Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/neuropathic-pain-therapeutics-summit/
LOCATION:Digital Event | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com?subject=Neuropathic Pain Therapeutics Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210824
DTEND;VALUE=DATE:20210827
DTSTAMP:20260515T201513
CREATED:20210602T122800Z
LAST-MODIFIED:20210602T122800Z
UID:30421-1629763200-1630022399@www.pharmajournalist.com
SUMMARY:PI3K Therapies Summit
DESCRIPTION:With 5 currently approved PI3K inhibitors in the market\, and countless investments\, M&As and candidates entering the clinical stages\, the PI3K pathways space has experienced significant growth in recent years. \nThe inaugural PI3K Pathways Summit is the industry’s only definitive conference providing in depth exploration of the biochemical basis of the pathway\, the successes and setbacks in gaining approval for PI3K inhibitors and the future advances which will potentially aid in overcoming issues with tolerability\, toxicity and resistance associated with PI3K inhibitors. \nJoin the online discussion at the only digital platform dedicated to bringing together the community of PI3K experts from large pharma\, innovative biotechs and research institutes for a unique opportunity to address the challenges of targeting the PI3K and AKT pathway\, evaluate strategies for overcoming these challenges to define next generation PI3K drugs and participate in cross-disciplinary discussions with fellow industry peers.
URL:https://www.pharmajournalist.com/event/pi3k-therapies-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210825
DTEND;VALUE=DATE:20210828
DTSTAMP:20260515T201513
CREATED:20210514T085007Z
LAST-MODIFIED:20210514T085007Z
UID:30162-1629849600-1630108799@www.pharmajournalist.com
SUMMARY:5th IPF Summit
DESCRIPTION:Overcome Translational & Clinical Challenges to Develop Disease-Modifying Drugs for IPF\, the Archetypal Fibrotic Disease. From Dissecting Mechanisms of Epithelial Dysfunction to Discovering Patient Reported Outcomes for More Meaningful Clinical Trials\, Uncover Scientific Advancements & Actionable Insights to Optimize IPF Drug Development. \nReturning with a revitalized agenda including 25 brand new speakers\, the hotly anticipated two-tracked summit is back! \nAs epithelial targets return to the limelight\, innovations in translational models hit their stride and clinical trial competition dramatically heats up; there’s more translational and clinically relevant science for IPF now than ever before\, catapulting this archetypal fibrotic disease right to the top of biopharma’s priority list. \n \nDedicated to providing you with the insights you need to create clinically defining IPF therapeutics\, this premier industry forum will unite industry experts from AstraZeneca\, Genentech\, Ionis\, AbbVie\, Gilead\, Lassen Therapeutics\, Pliant\, Galecto and more with leading academia\, for you to gain back-to-back insights on the science propelling IPF drug development forward. \nFrom dissecting the fibrotic lung microenvironment and comprehensively analyzing multiple translational models alongside bleomycin to including patient-reported outcomes as an endpoint in clinical trials; the 5th IPF Summit is the only end-to-end forum presenting scientific advancements as actionable insights for more innovative and clinically effective drug development. \nAs organizations across fibrosis\, autoimmunity and inflammatory disease turn their heads towards IPF in a bid to capitalize on its strategic opportunity\, Join 150+ IPF drug developers this August at this unique forum for a dynamic mix of formal presentations\, audience discussions\, panel discussions and organized networking and leave with the expertise your team needs to optimize your IPF R&D for 2021 and beyond. \nWant to learn more about our brand new 2021 agenda and expert speaker faculty? Click Here 
URL:https://www.pharmajournalist.com/event/5th-ipf-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210830
DTEND;VALUE=DATE:20210903
DTSTAMP:20260515T201513
CREATED:20210322T113138Z
LAST-MODIFIED:20210322T113138Z
UID:29478-1630281600-1630627199@www.pharmajournalist.com
SUMMARY:6th CAR-TCR Summit
DESCRIPTION:The CAR-TCR industry has started 2021 with a bang! With the 4th CAR-T gaining long-awaited approval\, Bristol-Myers Squibb have stepped onto the commercial stage\, and the CAR-TCR field continues to boom with excitement as the competition heats up. \nThe current approved therapies have encountered significant difficulties in the commercial market. Cell Therapies come with a high price tag\, little long-term efficacy data\, and expensive manufacturing processes. Now\, your community must gather to: \n\nAchieve consistency in manufacturing\, focusing on automation\, allogeneic platforms\, scalability\, and engineering techniques\nDemonstrate durable response with enhanced construct design\,optimized trial design\, and long-term follow-up data\nOvercome solid tumor hurdles with combination strategy\, specialized clinical delivery\, and next-generation engineering strategies\n\nThese challenges require ground-breaking work\, from discovery through to commercialization. Join the 6th CAR-TCR Summit to learn from the key opinion leaders\, and international innovators of the CAR-TCR community\, this September. \nSee more – https://ter.li/ofwzn3
URL:https://www.pharmajournalist.com/event/6th-car-tcr-summit/
LOCATION:Digital | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR